Accropeutics Secured $12 Million in Series B Plus Financing
NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ — Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12…